1105 Merck VelosBio
BioCentury & Getty Images


Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

VCs tout strong return as early data sparked interest in ADC

The biotech’s VCs are touting a strong return as early clinical data sparked interest in its ADC.

Nov 5, 2020 | 6:12 PM GMT

Although VelosBio appeared to be heading down the path to an IPO, the oncology company has instead accepted a $2.8 billion takeout offer from Merck now that the biotech’s

Read the full 792 word article

How to gain access

Continue reading with a
two-week free trial.